Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

FcRn: the neonatal Fc receptor comes of age

Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · see citing works

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978 · see citing works

Antibody Pharmacokinetics and Pharmacodynamics

Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909 · see citing works

Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin

Baselga, J. M., Pfister, D. G., Cooper, M. R., Cohen, R. B., Burtness, B. A., Bos, M. M. E. M., D’Andrea, G. M., Seidman, A. D., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741 · see citing works

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725 · see citing works

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.

Junghans, R. P., & Anderson, C. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5512 · Cited by 685 · see citing works

Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)

Dall’Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 648 · see citing works

Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance

Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 630 · see citing works

General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

Mager, D. E., & Jusko, W. J. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1014414520282 · Cited by 605 · see citing works

Evolution of Maternofetal Transport of Immunoglobulins During Human Pregnancy

Malek, A., Sager, R., Kuhn, P., Nicolaides, K. H., & Schneider, H. (1996) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.1996.tb00172.x · Cited by 559 · see citing works

Metabolic properties of IgG subclasses in man

Morell, A., Terry, W. D., & Waldmann, T. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106279 · Cited by 530 · see citing works

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Berinstein, N. L., Grillo-López, A. J., White, C. A., Bence‐Bruckler, I., Maloney, D. G., Czuczman, M. S., Green, D., Rosenberg, J., McLaughlin, P. J., & Shen, D. (1998) · Annals of Oncology · doi:10.1023/a:1008416911099 · Cited by 526 · see citing works

From the bench to the bedside: ways to improve rituximab efficacy

Cartron, G., Watier, H., Golay, J., & Solal‐Céligny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 521 · see citing works

Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies

Ober, R. J., Radu, C. G., Ghetie, V. F., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 502 · see citing works

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500 · see citing works

Elimination mechanisms of therapeutic monoclonal antibodies

Tabrizi, M. A., Tseng, C.-M. L., & Roskos, L. K. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03638-x · Cited by 479 · see citing works

Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice

Ghetie, V. F., Hubbard, J. G., Kim, J., Tsen, M. F., Lee, Y., & Ward, E. S. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260327 · Cited by 469 · see citing works

The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs

Roopenian, D. C., Christianson, G. J., Sproule, T. J., Brown, A. C., Akilesh, S., Jung, N., Petkova, S. B., Avanessian, L., Choi, E. Y., Shaffer, D. J., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3528 · Cited by 454 · see citing works

A Theoretical Model of γ-Globulin Catabolism

Brambell, F. W. R., Hemmings, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 451 · see citing works

Rituximab-Dependent Cytotoxicity by Natural Killer Cells

Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434 · see citing works

Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line

Dickinson, B. L., Badizadegan, K., Wu, Z., Ahouse, J. C., Zhu, X., Simister, N. E., Blumberg, R. S., & Lencer, W. I. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6968 · Cited by 433 · see citing works

Charge variants in IgG1

Khawli, L. A., Goswami, S., Hutchinson, R., Glover, Z. K., Yang, J., Wang, X., Yao, Z., Sreedhara, A., Cano, T., Tesar, D. B., et al. (2010) · mAbs · doi:10.4161/mabs.2.6.13333 · Cited by 420 · see citing works

Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life

Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S., & Lencer, W. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020400 · Cited by 403 · see citing works

Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics

Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F.-P., Fielder, P. J., & Khawli, L. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100261d · Cited by 398 · see citing works

Animal Scale-Up

Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397 · see citing works

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., & Saxne, T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22214 · Cited by 383 · see citing works

Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract

Wu, H., Pfarr, D. S., Johnson, S., Brewah, Y. A., Woods, R. M., Patel, N., White, W. I., Young, J. F., & Kiener, P. A. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.024 · Cited by 374 · see citing works

Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences

Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S., Patel, N., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368 · see citing works

A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.

Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 359 · see citing works

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

Lü, J., Bruno, R., Eppler, S., Novotny, W. F., Lum, B. L., & Gaudreault, J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0664-8 · Cited by 352 · see citing works

Pharmacologic target‐mediated drug disposition

Levy, G. (1994) · Clinical pharmacology and therapy · doi:10.1038/clpt.1994.134 · Cited by 342 · see citing works

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

Fasanmade, A. A., Adedokun, O. J., Ford, J. A., Hernandez, D., Johanns, J., Hu, C., Davis, H. M., & Zhou, H. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0718-4 · Cited by 328 · see citing works

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

Frost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323 · see citing works

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease

Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Khabbaz, H. J. A., Brown, A. C., Presta, L. G., Meng, Y. G., & Roopenian, D. C. (2006) · International Immunology · doi:10.1093/intimm/dxl110 · Cited by 315 · see citing works

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?

Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285 · see citing works

An Engineered Human IgG1 Antibody with Longer Serum Half-Life

Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282 · see citing works

Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.

Baxter, L. T., Zhu, H. J., Mackensen, D. G., & Jain, R. K. (1994) · PubMed · Cited by 280 · see citing works

Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates

Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 274 · see citing works

Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development

Lee, J. W., Kelley, M. M., King, L. E., Yang, J., Salimi-Moosavi, H., Tang, M. T., Lü, J., Kamerud, J., Ahene, A. B., Myler, H. A., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9251-3 · Cited by 271 · see citing works

Reduced elimination of IgG antibodies by engineering the variable region

Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq009 · Cited by 265 · see citing works

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

Bender, J. G., Adamson, P. C., Reid, J. M., Xu, L., Baruchel, S., Shaked, Y., Kerbel, R. S., Cooney, E., Stempak, D., Chen, H. X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9230 · Cited by 248 · see citing works

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis

Fasanmade, A. A., Adedokun, O. J., Olson, A., et al. (2010) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp48297 · Cited by 246 · see citing works

Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer

Bruno, R., Washington, C. B., Lü, J., Liebérman, G., Banken, L., & Klein, P. M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1026-z · Cited by 245 · see citing works

Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

Yeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starovasnik, M. A., & Lowman, H. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804182 · Cited by 237 · see citing works

Factors determining antibody distribution in tumors

Thurber, G. M., Schmidt, M., & Wittrup, K. D. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.004 · Cited by 224 · see citing works

Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.

Graff, C. P., & Wittrup, K. D. (2003) · PubMed · Cited by 207 · see citing works

Finally! the Brambell receptor (FcRB)

Junghans, R. P. (1997) · Immunologic Research · doi:10.1007/bf02786322 · Cited by 205 · see citing works

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.

den Broeder, A. A., van de Putte, L., Rau, R., Schattenkirchner, M., van Riel, P. L. C. M., Sander, O., Binder, C., Fenner, H., Bankmann, Y., Velagapudi, R. B., et al. (2002) · PubMed · Cited by 195 · see citing works

Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients

Ternant, D., Aubourg, A., Magdelaine–Beuzelin, C., et al. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318180e300 · Cited by 188 · see citing works

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Hale, G., Rebello, P., Brettman, L. R., Fegan, C., Kennedy, B., Kimby, E. K., Leach, M., Lundin, J., Mellstedt, H., Moreton, P., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0593 · Cited by 181 · see citing works

The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.

Mould, D. R., & Sweeney, K. (2007) · PubMed · Cited by 172 · see citing works

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Ducourau, É., Mulleman, D., Paintaud, G., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3386 · Cited by 165 · see citing works

Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization.

Huang, L.-H., Biolsi, S., Bales, K., & Kuchibhotla, U. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2005.11.012 · Cited by 153 · see citing works

Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

Ling, J., Zhou, H., Jiao, Q., & Davis, H. M. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337134 · Cited by 144 · see citing works

Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans

Mager, D. E., Woo, S., & Jusko, W. J. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.16 · Cited by 141 · see citing works

Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting

Danilov, S. M., Gavrilyuk, V., Franke, F. E., Pauls, K., Harshaw, D. W., McDonald, T. D., Miletich, D. J., & Muzykantov, V. R. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.280.6.l1335 · Cited by 135 · see citing works

Estimating the starting dose for entry into humans: principles and practice

Reigner, B. G., & Blesch, K. S. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0405-6 · Cited by 132 · see citing works

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

van Bueren, J. J. L., Bleeker, W. K., Bøgh, H. O., Houtkamp, M., Schuurman, J., van de Winkel, J. G. J., & Parren, P. W. H. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4010 · Cited by 127 · see citing works

Oncogenic mutations as predictive factors in colorectal cancer

Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117 · see citing works

Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath ^® ) in patients with chronic lymphocytic leukaemia and its link to treatment response

Mould, D. R., Baumann, A., Kuhlmann, J., Keating, M. J., Weitman, S., Hillmen, P., Brettman, L. R., Reif, S., & Bonate, P. L. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02914.x · Cited by 116 · see citing works

Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys

Deng, R., Loyet, K. M., Lien, S., Iyer, S., DeForge, L. E., Theil, F., Lowman, H. B., Fielder, P. J., & Prabhu, S. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031310 · Cited by 113 · see citing works

Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis

Xu, Z., Seitz, K., Fasanmade, A. A., Ford, J. A., Williamson, P., Xu, W., Davis, H. M., & Zhou, H. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008316886 · Cited by 109 · see citing works

Pharmacokinetics/Pharmacodynamics of Nondepleting Anti-CD4 Monoclonal Antibody (TRX1) in Healthy Human Volunteers

Ng, C. M., Stefanich, E. G., Anand, B. S., Fielder, P. J., & Vaickus, L. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8814-3 · Cited by 109 · see citing works

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4

Bumbaca, D., Wong, A., Drake, E. A., Reyes, A. E., Lin, B. C., Stéphan, J.-P., Desnoyers, L., Shen, B., & Dennis, M. S. (2011) · mAbs · doi:10.4161/mabs.3.4.15786 · Cited by 105 · see citing works

Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited

Wang, W., & Prueksaritanont, T. (2010) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.708 · Cited by 105 · see citing works

An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab

Ternant, D., Mulleman, D., Degenne, D., et al. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000189901.08684.4b · Cited by 104 · see citing works

The clinical pharmacology of therapeutic monoclonal antibodies

Roskos, L. K., Davis, C., & Schwab, G. M. (2004) · Drug Development Research · doi:10.1002/ddr.10346 · Cited by 102 · see citing works

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

Putnam, W. S., Prabhu, S., Zheng, Y., Subramanyam, M., & Wang, Y. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.001 · Cited by 101 · see citing works

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of Cetuximab

Ternant, D., Cézé, N., Piller, F., Degenne, D., Dorval, E., Watier, H., Lecomte, T., & Paintaud, G. (2009) · HAL · Cited by 100 · see citing works

Pharmacokinetic Drug‐Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check

Seitz, K., & Zhou, G. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007306958 · Cited by 93 · see citing works

Therapeutic Monoclonal Antibody Concentration Monitoring: Free or Total?

Kuang, B., King, L., & Wang, H. F. (2010) · Bioanalysis · doi:10.4155/bio.10.64 · Cited by 93 · see citing works

A Phase 1 Study of PAmAb, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers

Subramanian, G. M., Cronin, P., Poley, G. E., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430708 · Cited by 93 · see citing works

Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis

Ng, C. M., Joshi, A., Dedrick, R. L., Garovoy, M. R., & Bauer, R. J. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-5642-4 · Cited by 92 · see citing works

Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies.

Ezan, E., & Bitsch, F. (2009) · Bioanalysis · doi:10.4155/bio.09.121 · Cited by 90 · see citing works

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first‐in‐human trials of high‐risk biologics

Agoram, B. M. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03297.x · Cited by 85 · see citing works

On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

Lowe, P. J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R., & Howard, D. (2007) · Xenobiotica · doi:10.1080/00498250701648008 · Cited by 82 · see citing works

Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head‐and‐neck cancer xenografts

Verel, I., Heider, K., Siegmund, M., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10369 · Cited by 79 · see citing works

A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life

Yeung, Y. A., Wu, X., Reyes, A. E., Vernes, J.-M., Lien, S., Lowe, J. A., III, Maia, M., Forrest, W. F., Meng, Y. G., Damico, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4580 · Cited by 78 · see citing works

Pharmacokinetics and Pharmacodynamics of SB-240563, a Humanized Monoclonal Antibody Directed to Human Interleukin-5, in Monkeys

Zia‐Amirhosseini, P., Minthorn, E. A., Benincosa, L. J., Hart, T. K., Hottenstein, C. S., Tobia, L. A. P., & Davis, C. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35210-3 · Cited by 77 · see citing works

Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients

Marathe, A., Peterson, M. C., & Mager, D. E. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137703 · Cited by 75 · see citing works

Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets.

Bunescu, A., Seideman, P., Lenkei, R., Levin, K., & Egberg, N. (2004) · PubMed · Cited by 75 · see citing works

Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

Yang, B., Lum, P., Chen, A., Arends, R., Roskos, L. K., Smith, B. P., & Ruixo, J. J. P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535970-000000000-00000 · Cited by 66 · see citing works

An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab

Cézé, N., Ternant, D., Piller, F., Degenne, D., Azzopardi, N., Dorval, E. D., Watier, H., Lecomte, T., & Paintaud, G. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181b33da3 · Cited by 64 · see citing works

Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice

Newkirk, M. M., Novick, J., Stevenson, M. M., et al. (1996) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1996.d01-847.x · Cited by 61 · see citing works

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications

Reff, M. E., & Heard, C. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00132-9 · Cited by 60 · see citing works

Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma

Scheidhauer, K., Wolf, I., Baumgartl, H.-J., von Schilling, C., Schmidt, B., Reidel, G., Peschel, C., & Schwaiger, M. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0820-7 · Cited by 56 · see citing works

Passage of intravenous immunoglobulin and interaction with the CNS.

Wurster, U., & Haas, J. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.suppl.21 · Cited by 51 · see citing works

Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons

Kagan, L., Abraham, A. K., Harrold, J. M., & Mager, D. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0098-6 · Cited by 50 · see citing works

Target-mediated drug disposition model for drugs that bind to more than one target

Gibiansky, L. V., & Gibiansky, E. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9163-3 · Cited by 50 · see citing works

Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species

Vugmeyster, Y., Szklut, P., Wensel, D. L., Ross, J. E., Xu, X., Awwad, M., Gill, D. S., Tchistiakov, L., & Warner, G. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0405-x · Cited by 50 · see citing works

Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty

Mager, D. E., Mascelli, M. A., Kleiman, N. S., Fitzgerald, D. J., & Abernethy, D. R. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057299 · Cited by 49 · see citing works

In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus

Vugmeyster, Y., Guay, H., Szklut, P., Qian, M., Jin, M., Widom, A., Spaulding, V., Bennett, F., Lowe, L. D., Andreyeva, T. A., et al. (2010) · mAbs · doi:10.4161/mabs.2.3.11850 · Cited by 48 · see citing works

Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin

Jolling, K., Ruixo, J. J. P., Hemeryck, A., Vermeulen, A., & Greway, T. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.01.002 · Cited by 46 · see citing works

Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium

Trippett, T. M., Herzog, C. E., Whitlock, J. A., Wolff, J. E. A., Kuttesch, J. F., Bagatell, R., Hunger, S. P., Boklan, J., Smith, A., Arceci, R. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8975 · Cited by 44 · see citing works

An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

Ternant, D., Cézé, N., Lecomte, T., et al. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181ef582a · Cited by 40 · see citing works

Pharmacokinetics of Murine Anti-Human CD3 Antibodies in Man Are Determined by the Disappearance of Target Antigen

Meijer, R. T., Koopmans, R. P., ten Berge, I. J. M., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.346 · Cited by 40 · see citing works

TISSUE DISTRIBUTION AND RECEPTOR-MEDIATED CLEARANCE OF ANTI-CD11A ANTIBODY IN MICE

Coffey, G., Fox, J. A., Pippig, S. D., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002584 · Cited by 38 · see citing works

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing

Koon, H. B., Severy, P. B., Hagg, D. S., Butler, K. L., Hill, T., Jones, A. G., Waldmann, T. A., & Junghans, R. P. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.06.007 · Cited by 36 · see citing works

Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H.

Hutchins, J., Kull, F. C., Bynum, J. M., et al. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.11980 · Cited by 34 · see citing works

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients

Ng, C. M., Bai, S., Takimoto, C. H. M., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1023-8 · Cited by 31 · see citing works

In vivo detection of intervertebral disk injury using a radiolabeled monoclonal antibody against keratan sulfate.

Kairemo, K., Lappalainen, A. K., Kääpä, E., et al. (2001) · PubMed · Cited by 19 · see citing works

Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody.

Duconge, J., Castillo, R., Crombet, T., Alvarez, D., Matheu, J., Vecino, G., Alonso, K., Beausoleil, I., Valenzuela, C., Bécquer, M. A., et al. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.10.015 · Cited by 13 · see citing works

Exposure-Effect Population Model of Inolimomab, a Monoclonal Antibody Administered in First-Line Treatment for Acute Graft-Versus-Host Disease

Dartois, C., Freyer, G., Michallet, M., et al. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746050-00004 · Cited by 13 · see citing works

The Fate and Function of Therapeutic Antiaddiction Monoclonal Antibodies across the Reproductive Cycle of Rats

Hubbard, J. J., Laurenzana, E. M., Williams, D. K., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175083 · Cited by 12 · see citing works

Pharmacokinetics, Biodistribution, and Radioimmunotherapy with Monoclonal Antibody 776.1 in a Murine Model of Human Ovarian Cancer

Berger, M. A., Masters, G. R., Singleton, J., et al. (2005) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2005.20.589 · Cited by 11 · see citing works

A novel method for quantitative measurement of a therapeutic monoclonal antibody in the presence of its target protein using enzymatic digestion

Doucet, J., & Avraméas, A. (2010) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2010.01.033 · Cited by 11 · see citing works

In Vitro–In Vivo Correlations of Pharmacokinetics, Pharmacodynamics, and Metabolism for Antibody Therapeutics

Boswell, C. A., Deng, R., Lin, K., et al. (2009) · CRC Press eBooks · doi:10.3109/9781420078077-5 · Cited by 8 · see citing works

Roche plans for more convenient-to-use Herceptin and Rituxan

Ratner, M. A. (2010) · Nature Biotechnology · doi:10.1038/nbt0410-298 · Cited by 6 · see citing works

High Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation as Salvage Therapy for HIV-Associated Lymphoma: Result of the GICAT Study.

Re, A., Michieli, M., Cattaneo, C. M., et al. (2007) · Blood · doi:10.1182/blood.v110.11.23.23 · Cited by 2 · see citing works

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works

Clinical pharmacology considerations for the development of immune checkpoint inhibitors

Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.990 · Cited by 124 · see citing works

Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics

Bumbaca, D., Boswell, C. A., Fielder, P. J., & Khawli, L. A. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9369-y · Cited by 119 · see citing works

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

Leabman, M. K., Meng, Y. G., Kelley, R. F., DeForge, L. E., Cowan, K. J., & Iyer, S. (2013) · mAbs · doi:10.4161/mabs.26436 · Cited by 110 · see citing works

Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development

Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69 · see citing works

The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection

Rajšić, I., Pavlović, N., Milijašević, B., et al. (2019) · Vojnosanitetski pregled · doi:10.2298/vsp190430126r · Cited by 3 · see citing works

Pharmacokinetics of monoclonal antibody HAb 18 and its F(ab^)_(2) and fab fragments in mice

Yu, J., Sui, Y.-F., Chen, Z., et al. (1996) · Europe PMC (PubMed Central) · Cited by 3 · see citing works

Evaluation of pharmacokinetic properties of vitacoxib in fasted and fed horses

Wang, J., Xue, J., Kong, J., et al. (2018) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12703 · Cited by 9 · see citing works

Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant FVIII, in hemophilia A mice

Gu, R., Liu, L., Xie, L., et al. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.121 · Cited by 6 · see citing works

Pharmacodynamic Drug–Drug Interactions

Hinder, M. (2010) · Springer eBooks · doi:10.1007/978-3-540-89891-7_29 · Cited by 8 · see citing works